There are six major steps in the management of patients with neuroendocrine tumors (NETs) (carcinoids and pancreatic endocrine tumors). One of the steps that is increasing in its importance is the need to assess primary tumor location and tumor extent in these patients. Without such information, it is not possible to adequately manage these patients. Conventional imaging studies (CT scan, MRI, ultrasound, angiography) 122 patients and shows that the use of SRS changed management in 47 percent of patients according to six different criteria when the patients were stratified according to their principal management problem. Determining whether liver metastases were present is one of the major goals of tumor localization studies and is frequently a source of confusion because of the difficulty in distinguishing small NETs liver metastases from hemangiomas. In the second stucy, the ability of SRS and other tumor localization methods to distinguish these two possibilities was assessed in 15 patients with small hemangiomas and 15 patients with small hepatic metastases (mean size 1.3 cm). SRS correctly identified 93 percent of the patients with liver metastases and was not positive in any patient with a hemangioma, suggesting it was not a liver metastases. SRS had greater negative and positive predictive value than conventional studies. Based on these two studies, and SRS's greater sensitivity and fiscal considerations, it is proposed that SRS should be the initial tumor imaging study in all NETs except insulinomas, and algorithms for the use of other localization studies in both NETs and insulinomas are proposed.
cated to localize NETs in different studies. Whereas it is now established that for all NETs, except insulinomas, SRS has the greatest sensitivity, it remains unclear whether this increased sensitivity translates into increased clinical usefulness. It, therefore, remains unclear based on fiscal and clinical considerations what should be the recommended algorithm for the use of the different localization methods. To address this issue, we have recently performed two prospective studies on patients with gastrinomas. In this paper, the methods and results of each are summarized and based on these results, an algorithm for localization studies in NETs is proposed. One study assessed the role of SRS in management in 122 patients and shows that the use of SRS changed management in 47 percent of patients according to six different criteria when the patients were stratified according to their principal management problem. Determining whether liver metastases were present is one of the major goals of tumor localization studies and is frequently a source of confusion because of the difficulty in distinguishing small NETs liver metastases from hemangiomas. In the second stucy, the ability of SRS and other tumor localization methods to distinguish these two possibilities was assessed in 15 
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to synthesize multiple peptides; they both synthesize shared secreted proteins and cytoplasmic proteins such as chromogranin, synaptophysin and neuron-specific enolase; they have similar biologic behavior, and the management considerations are similar with each. [1] [2] [3] [4] [5] . The shared similar steps in management of NETs are summarized in Table 1 . All require the establishment of the diagnosis and determination of whether the tumor is associated with a functional syndrome (i.e., gastrinoma, VIPoma, carcinoid syndrome, etc.). Tumor localization and tumor extent are essential for planning the proper course of management [1, 6] and will be discussed in detail below. Recently, it has become increasingly apparent that inherited syndromes can be associated with either carcinoids (von Recklinghausen's syndrome, multiple endocrine neoplasia-type I [MEN-I]) or PETs (MEN-I, von Hippel-Landau disease, tuberous sclerosis, von Recklinghausen's syndrome), and their recognition is important because it alters management [7] [8] [9] . All patients that have NETs have two treatment problems in that if the tumors are functional, treatment must be directed at the hormone excess state and because most are malignant, treatment must be directed at the tumor itself [1, [8] [9] [10] (Table 1) . Lastly, all patients with NETs require long-term follow-up because in many cases, even though the rate of growth is slow, the true recurrence rate is unclear. For each of the management steps in Table 1 , an algorithm and fiscal comparison using different approaches could be done. In this article, the analysis will be restricted to such considerations in NET tumor localization and extent.
PURPOSE OF NET LOCALIZATION STUDIES AND
LOCALIZATION METHODS USED NET tumor localization studies are necessary for three primary reasons: first, to determine resectability by determining if surgical resection is indicated, by excluding extensive metastatic disease [6, [11] [12] [13] ; second, to localize the primary tumor to increase the likelihood of surgical resection [6, 14, 15] ; third, to assess tumor progression by determining growth to select the appropriate therapy [2, 6] .
-Numerous imaging modalities have been widely used to localize NETs including conventional imaging studies (ultrasound, computed tomographic scanning [CT scan], magnetic resonance imaging [MRI] and selective angiography) [6, 16] , and functional localization by measuring hormonal gradients either by portal venous sampling, or in hepatic venous samples under basal conditions, or after secretin or calcium intra-arterial infusion [17] [18] [19] . Recently, two newer methodologies, endoscopic ultrasound (EUS) [20] and somatostatin receptor scintigraphy (SRS) [21] [22] [23] [23, 31, 32] . Patients with liver metastases undergo imaging to determine whether cytoreductive surgery should be considered [11, 33] , tumoricidal treatment begun [2, 34, 35] , liver transplantation considered [36] [37] [38] , or to determine the response of some tumoricidal treatment [2] . In contrast, in patients without hepatic metastases, imaging studies are usually performed to localize a possible primary tumor that could be resected [6, 39] . Patients with MEN-I with a functional PET that is not a gastrinoma undergo localization studies to find which of numerous tumors is the functional one [17, 32] . In contrast, in patients with MEN-I with a nonfunctional PET or gastrinoma, some groups recommend routine surgery only if the tumor is greater than 2.5 cm [32, 40, 41] . Therefore, imaging needs to be used that clearly establishs the size of the lesion. Third, the different localization methods vary considerably in cost [42] (Table 2) , and, therefore, fiscal considerations are becoming increasingly a factor in which studies or combinations may be done [31, 42] . In general, SRS costs twice as much as a CT scan and, in some cases MRI, and generally costs slightly less than angiography ( Table 2 ). The recent large NIH study [23] in patients with gastrinomas demonstrated that the SRS was equal in sensitivity to the combination of all conventional imaging studies (ultrasound, CT scan, MRI, angiography; total cost: $5500). Therefore, if SRS is also equally effective in management in these situations, it would also be more cost-effective than this combination of conventional imaging studies. In practice, for SRS to be completely cost-effective it must just be equal or superior to a combination of two localization studies. Generally, only two localization studies are performed in most patients with NETs. In the past, these studies usually were ultrasound or CT and MRI or angiography and more recently, ultrasound, CT or MRI and EUS [22, 29, 30, [43] [44] [45] [46] .
Whereas numerous studies have established the sensitivity of SRS, few studies have attempted to assess the usefulness of SRS in clinical management in sufficient numbers of patients to allow a clear definition of its value compared to other conventional localization methods [23, 47, 48] . Recently two studies have been performed at the National Institutes II. The only study identifying liver metastases in more than one lobe.
III. The only study identifying a possible primary tumor in a patient who was a surgical candidate or its detection changed management. IV. The only study identifying bone metastases that changed treatment. V. The only study identifying additional distant metastases that changed management. VI. Useful in clarifying equivocal lesion(s) seen on conventional imaging studies that resulted in altered management.
of Health on patients with gastrinomas that address these issues. The remainder of this paper will briefly review these studies and present an algorithm for tumor localization studies based on extrapolation of these results and those from other studies on neuroendocrine tumors.
NIH PROSPECTIVE STUDY ON THE ABILITY OF SRS TO ALTER MANAGEMENT IN PATIENTS WITH GASTRINOMAS
Methods in SRS management study
One hundred twenty-two consecutive patients with Zollinger-Ellison syndrome were studied in this NIH prospective study [31] . Each patient was assigned to one of five different clinical categories ( Table 2 ) to 100 percent in the patients with metastatic liver disease (category V, Table 2 ). The results for the ability of SRS to alter management in all patients (n = 122) and according to the five different clinical categories are shown in Figure 1 stratified by the reason that SRS changed clinical management. SRS changed management overall in 47 percent of the patients (Figure 1 -top, any reason) and approximately equally affected each of the clinical categories except the cured category (category II, Table 2 ).
The basis for SRS altering clinical management varied depending on the clinical category ( Figure 1 ). In patients in clinical category I for preoperative evaluation, SRS primarily changed management by clarifying equivocal lesions (41 percent) or being the only study to identify a primary lesion (6 percent). Figure 2 shows an example of such a patient in whom the MRI and all other imaging studies were negative preoperatively; however, the SRS showed a pancreatic head lesion, and at surgery, the patient was cured after removal of a 0.5 cm gastrinoma in a pancreatic head lymph node. In clinical category II (cured patients), SRS changed management by clarifying equivocal lesions (22 percent) from conventional imaging studies that could represent metastases or recurrence. A number of these lesions were questionable liver metastases, and one aspect of this is dealt with in the second NIH study discussed below. SRS altered clinical management in 44 percent of patients in clinical category III (not cured post-surgery) with the reasons being clarification of equivocal findings of conventional imaging studies (26 percent), the only study to identify a recurrent gastrinoma leading to repeat exploration (22 percent), and identifying new liver metastases in 4 percent. In clinical category IV (patients with no previous surgery), SRS altered management in 50 percent by clarifying equivocal conventional imaging studies (25 percent) or being the only study to demonstrate a primary lesion that altered management. SRS altered management in 60 percent of the patients in the metastatic liver disease category, primarily by clarifying equivocal lesions for conventional imaging studies (32 percent) , being the only modality to identify bilateral liver metastases whose identification precluded surgery; being the only modality to identify any bone metastases that led to institution of anti-tumor therapy (8 percent); and being the only Figure 1 ; Table 3 ).
modality to identify additional metastases that altered management (8 percent). An example of the latter category is shown in Figure 3 for a patient complaining of upper back pain with metastatic gastrinoma. Table 3 ).
laboratory characteristics (BAO, MAO, fasting gastrin level), in whether the patients had or had not undergone a previous gastrinoma resection, or whether liver metastases were present or absent (p = .06). SRS was more likely to change management in patients with any positive conventional imaging study (p < .001), a possible primary lesion on a conventional imaging study (p < .001) or possible liver metastases on conventional imaging studies (p < .0001).
CONCLUSIONS OF THE NIH SRS MANAGEMENT STUDY It was concluded that SRS, because of its ability to alter clinical management combined with its high sensitivity shown both in this study [31] and in previous studies [21-23, 28, 29, 45, 46, 49-51] , high specificity [21, 23, 27] , and simplicity and ability to image the entire body, should be the initial imaging modality for patients with gastrinoma. Because SRS is as sensitive as all conventional imaging studies combined, and two conventional studies are usually performed, the initial use of SRS based on sensitivity alone is cost-effective. Furthermore, because somatostatin receptor density is similarly high in all other NETs except insulinomas [21, 22, 27, 52] and because of their similar biologic behavior to gastrinomas [1, 2] , it is likely that these conclusions also apply to less common PETs and carcinoid tumors [31] . A recent review [53] , presents data from a few studies that demonstrate SRS did not detect a number of small metastases in the liver in patients with metastatic carcinoids. Whether this result is due to the small size of the metastases or is specific for carcinoid tumors is presently unknown.
In the above NIH study, the main reason for SRS changing clinical management was the clarification of equivocal lesions on conventional imaging studies (29 percent). This was more than twice as common a reason for changing management than any other factor and made up more than 50 percent of the changes in management in each clinical category ( Figure 1) . One of the main lesions requiring clarification was the question of possible liver metastases identified on CT, MRI (particularly the STIR images [short TI inversionrecovery pulse sequences]) or angiography. One of the main reasons for this confusion is that liver metastases from NETs are highly vascular [16] , may be few in number and in many patients are small when first discovered (<1-2 cm); therefore, they may be very difficult to differentiate from other small vascular tumors of the liver, particularly hemangiomas, using the standard imaging techniques (MRI, CT, angiography) [54] [55] [56] .
Cavernous hemangiomas of the liver are the most common benign tumor of the liver, occurring in 7.5-15 percent of autopsy cases [57, 58] . Cavernous hemangiomas can be difficult to distinguish from small metastases in patients with malignant NETs because they also are hypervascular and may be multiple in 10-50 percent of cases [57, 59] .
Investigations such as 99MTc-labeled red blood cell scintigraphy, heavily T2-weighted MRI, and dynamic bolus-enhanced CT or MRI are frequently falsely negative in hemangiomas less than 1.5 cm in diameter [54, 56, [60] [61] [62] [63] . For example, in one recent study 99MTc RBC scanning with SPECT imaging only detected 58 percent of 24 hemangiomas 1-1.9 cm in diameter [54] . There have been a number of reports of patients thought to have hepatic hemangiomas that later proved to be NETs [64] [65] [66] . In our study on the role of SRS in management presented above, one patient had both a liver metastasis and a hepatic hemangioma verified at surgical exploration, and although both were seen on MRI and angiography, only the metastasis was seen on the SRS. This case raised the possibility that the SRS might not generally identify hepatic hemangiomas, why it would identify almost all liver metastases and, thus, might be able to distinguish these two vascular abnormalities. High densities of somatostatin receptors are found in intestinal veins in patients with inflammatory bowel disease and in peritumoral veins, but not in normal veins or other vascular structures [67, 68] ; however, it is unknown if an increased density of somatostatin receptors occurred in hemangiomas. To examine this possibility and to determine whether SRS was superior to other imaging studies in distinguishing whether small hepatic vascular lesions in patients with gastrinomas were metastases or hemangiomas, an additional study was performed [56] . ZES (29 
NIH STUDY OF THE ABILITY OF SRS AND CONVENTIONAL IMAGING STUDIES (CT, MRI, ANGIOGRAPHY) TO DISTINGUISH HEPATIC HEMANGIOMAS FROM METASTASES IN PATIENTS WITH GASTRINOMAS
Methods for NIH SRS hemangioma study. Of 137 consecutive patients with gastrinoma admitted to the NIH, 29 patients were found to have small hypervascular liver lesions (< 3 cm diameter; mean: 1.3 cm) with less than five lesions per hepatic lobe or nine lesions per liver, and these patients were included in this study. Twenty-six of these patients had multiple previous NIH admissions (mean: seven admissions), and three patients were being investigated for the first time. Fifteen patients including three new patients were determined to have hepatic hemangiomas by the presence of one or more of the following: hemangioma observed during surgery (n = 3), by biochemical evidence of cure of the Zollinger-Ellison syndrome after resection of an extrahepatic gastrinoma (n = 7) or by the absence of growth of the lesion on standard imaging studies after a mean follow-up of four years (n = 5). In 15 patients, the hepatic lesions were shown to be metastatic tumor histologically by a CT-or ultrasound-guided percutaneous liver biopsy or during laparotomy. One patient was found to have both a hepatic hemangioma and a single liver metastasis. Each of the 29 patients ) show a hepatic vascular lesion (arrows) that could represent a metastasis from the gastrinoma. The SRS (right panel) was negative. This hepatic lesion was determined to represent a hemangioma because with long-term follow-up it did not increase in size and the patient remained cured post resection of a duodenal tumor with normal fasting gastrin levels and a negative secretin test [97] .
underwent a CT scan, MRI, selective angiography and SRS. A single radiologist who did not know the diagnosis read each film, determining whether any hepatic lesion could be seen and whether it was a hemangioma, metastasis, or whether it could not be determined which of the two vascular lesions it was. The CT criteria [60, 61, [69] [70] [71] and selective angiography criteria [72] [73] [74] were those previously described. On MRI both metastases and hemangiomas were of low signal intensity on TI-weighted images and bright on STIR images. Extreme brightness compared to the kidney or spleen was more suggestive of hemangioma.
Results of SRS hemangioma study There were 31 hemangiomas in the 15 patients with a mean number of 2.1/patient (range: 1-9) with a mean size of 1.3 + 0.1 cm (range: 0.5 -2.8 cm) with 60 percent less than 1 cm. There were 45 metastases in 15 patients with a mean of 2.5 lesions/patient (range: 1-8), with a mean size of 1.3 + 0.1 (range: 0.5 -3 cm) (Figure 4 ). The data, whether analyzed on a per patient basis or a per lesion basis (Figure 4) , showed similar results. SRS detected a hepatic metastases in 93 percent of patients with liver metastases. In patients with metastases, SRS and angiography were not significantly different in identifying the number of lesions, and both were significantly better than CT or MRI (Figure 4 , left panel). However, for correctly identifying a lesion as a metastasis, the SRS correctly identified 84 percent of all metastases in 93 percent of the patients and was significantly better than any of the other studies or a combination of all of the studies (p < .01) ( Figure  4, left) . In contrast, SRS was negative in all 15 patients with hemangiomas. Angiography and MRI both identified hepatic vascular lesions in over 70 percent of patients with hepatic hemangiomas. In contrast, angiography correctly identified 77 percent as hemangiomas, whereas CT and MRI correctly identified less than 10 percent (Figure 4 , right panel). Figure 5 shows an example of such a patient in which the MRI and angiogram both demonstrate a possible hepatic metastasis, whereas the SRS was negative. This patient Figure 4 . Data are from [56] .
was biochemically cured post-gastrinoma resection and has remained disease-free for two years, confirming that the hepatic vascular lesion is a hemangioma.
SRS was superior to all of the other studies for negative and positive predictive values and equal to CT scanning and angiography in terms of specificity ( Figure 6 ). Conclusions ofNIH SRS hemangioma study SRS is an excellent imaging modality for distinguishing small vascular hepatic metastases in patients with gastrinomas from small hemangiomas. Because hepatic metastases in patients with gastrinoma are similar in terms of density of somatostatin receptors, hypervascularity and CT, MRI and angiographic appearance of those occurring in other malignant NETs, SRS will likely be similarly useful in these syndromes. The practical ability of SRS to make this distinction and affect clinical management was shown in the previous study in which more than 50 percent of all the changes in management caused by SRS were due to clarification of equivocal lesions and at least 50 percent of these were related to equivocal hepatic vascular lesions. [31] and is particularly helpful in clarifying equivocal results from conventional imaging studies, especially in regard to the identity of small vascular metastasis in the liver [56] . In the management study, the nearly one-half of all cases in which SRS altered management represents a measure of the clinical gain over existing conventional imaging studies by the use of SRS. In numerous studies in patients with different NETs except insulinomas, SRS has been shown to have either greater sensitivity than any conventional imaging study (i.e., ultrasound, CT scan, MRI, selective angiography) or is at least equal or better than all imaging studies combined [21, 23, 28-31, 44, 48, 56] . Therefore, performing just the SRS would be a much more cost-effective approach than performing each of the conventional imaging studies (Table 2 ) [31, 42] . Because of its increased sensitivity and ability to image the entire body, SRS gives information on the location of the primary tumor, possible regional tumor metastases and distal metastases. Therefore, it provides at least equal information to the conventional imaging studies in patients in which it did not change management, as well as the additional information it gives in patients in which it did change management. Lastly, the specificity | Neuroendocrine Tumor (Except insulinoma) [21, 22] , and they also may possess somatostatin receptors that do not bind octroetide, especially subtypes sstl and sst4, and only 14-50 percent are localized by SRS in some studies [22, 27, 30] . Each of the other neuroendocrine tumors can be malignant [21, 22, 78] , and the treatment decisions are similar to that for gastrinomas in similar stages of their management [1, 2, 8, 26, 79] . Based on these considerations, the tumor localization approach as shown in Figure 7 for all NETs except insulinomas is recommended; and for insulinomas, the algorithm shown in Figure 8 is recommended. For all NETs except insulinomas the SRS should be the initial localization study based on its sensitivity, specificity, ability to image the entire body and cost-effectiveness. If liver metastases are seen on the SRS and if they are extensive in both lobes, which is the case in 80-90 percent of patients with hepatic metastases, then surgical resection is not generally a consideration [1, 2, 8, 11-13, 33, 80] . To confirm the diagnosis, a CT-or ultrasound-guided biopsy can be performed (Figure 7) . It is not yet established how changes in size or intensity of the SRS image relates to change in tumor size assessed by measuring tumor growth with conventional imaging studies; therefore, we recommend that if liver metastases are seen on SRS, a conventional imaging study be performed to facilitate follow-up assessment of tumor growth. In our experience, the MRI, especially the STIR images, gives the best results and is the most sensitive [6, 55] . If the metastases are limited and cytoreductive surgery is considered [1, 2, 8, 11-13, 33, 80] , we would recommend selective angiography and MRI to define the relationship of the metastases to the vasculature and clearly define the tumor size and location ( Figure 7) . A recent study [24] demonstrates that the use of the intra-arterial injection of secretin during angiography with hepatic venous sampling can be useful and will change management in 22 percent of cases with limited or equivocal hepatic lesions in patients with gastrinomas. This study [24] did not include the use of SRS, and it is unclear whether intra-arterial secretin with hepatic venous gastrin gradients would be as useful if the SRS did not clarify the situation. Therefore, until this study is done it is not recommended routinely.
If SRS does not show liver metastases in a non-insulinoma NET, no other imaging studies need to be performed to exclude liver metastases because the SRS detected 92 percent of patients with liver metastases, and the addition of all conventional imaging studies only increased the sensitivity by 4 percent in one large study [23] . However, additional studies to localize the primary tumor may be indicated (Figure 7) . If the primary tumor is not localized on SRS in patients with a PET, endoscopic ultrasound should be the next procedure performed. EUS localizes almost all pancreatic PETs although it may miss as high as 50 percent of duodenal PETs [43, 81, 82] . If it is negative, angiography with selective intra-arterial injection of secretin or calcium and hepatic venous sampling should be performed [17] [18] [19] . At surgery, intraoperative ultrasound [14, 83] should be used and in the case of gastrinomas a duodenal exploration with duodenotomy [84, 85] is essential, with prior transillumination of the duodenum to assist in the placement of the duodenotomy and tumor localization [86] . In a patient with a carcinoid tumor with no liver metastases, CT or MRI are indicated to localize the primary tumor and its extent ( Figure 7 ).
In patients with insulinomas, MRI should be the initial imaging study to exclude liver metastases that occur in 5-15 percent of patients with insulinomas in different series [9, [87] [88] [89] [90] [91] . In the algorithm (Figure 8) , we have recommended an MRI be done because we find it easier to see PET metastases to the liver on the STIR sequences than with CT. If no liver metastases are seen, the localization study of choice is endoscopic ultrasound, which is reported to identify an insulinoma in 77-93 percent of patients [20, 30, 92, 93] . If this is negative, angiography with intra-arterial calcium injection with hepatic venous sampling for insulin gradients should be performed, because it is recently reported to be positive in 83-88 percent of cases [19, 94, 95] . At surgery, intra-operative ultrasound has been shown to be particularly helpful in localizing intrapancreatic endocrine tumors such as insulinomas and should be used [14, 80, 83, 96] .
